Cost-effectiveness of gene therapy with etranacogene dezaparvovec versus factor IX prophylaxis in men with hemophilia B in Brazil

Main Article Content

Juliana Alvares-Teodoro Ana Clara Silva Mendes Ricardo Mesquita Camelo Augusto Afonso Guerra Júnior Francisco de Assis Acurcio

Abstract

Background: The high costs and uncertainties surrounding the effectiveness and safety of new health technologies necessitate continuous evaluation to balance access and sustainability within Brazil’s Unified Health System.


Aims: Cost-effectiveness analysis comparing etranacogene dezaparvovec versus factor IX prophylaxis in people with hemophilia B from the Brazilian healthcare system perspective.


Methods: A cost-effectiveness analysis was conducted using TreeAge Pro software. A decision tree model compared the costs and effectiveness of etranacogene dezaparvovec versus factor IX prophylaxis in preventing bleeding in adult male with severe or moderately severe hemophilia B over a three-year horizon. A deterministic sensitivity analysis identified variables impacting incremental cost-effectiveness ratio.


Results: etranacogene dezaparvovec incurred a cost of USD 2,335,747 (BRL 10.810.993) versus USD 46,451 (BRL 232.256) for plasma-derived factor IX prophylaxis, with an incremental cost of USD 2,115,747 (BRL 10.578.737). The effectiveness (number of bleeding events) was 2.86 for etranacogene dezaparvovec and 10.95 for factor IX prophylaxis, with etranacogene dezaparvovec avoiding 8.09 additional bleeding events. The incremental cost-effectiveness ratio was USD 261,436 (BRL1.307.179) per bleeding event avoided. Sensitivity analysis revealed treatment duration as the most impactful variable on incremental cost-effectiveness ratio, contributing to 80% of model uncertainty.


Discussion: International studies suggest that etranacogene dezaparvovec is cost-effective and dominant in multiple contexts, particularly when compared to extended half-life recombinant factor IX (rFIX-EHL), offering greater quality-adjusted life years for people with hemophilia B at lower long-term costs. However, a lack of robust data underscores the need for ongoing monitoring and careful evaluation before incorporation by the health system. It should also be noted that high pricing of new treatments like etranacogene dezaparvovec poses challenges for Brazil’s Unified Health System sustainability and equitable access.

Keywords: Hemophilia B, Etranacogene dezaparvovec, Factor IX prophylaxis, Cost-effectiveness analysis, Brazilian healthcare system

Article Details

How to Cite
ALVARES-TEODORO, Juliana et al. Cost-effectiveness of gene therapy with etranacogene dezaparvovec versus factor IX prophylaxis in men with hemophilia B in Brazil. Medical Research Archives, [S.l.], v. 13, n. 1, jan. 2025. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6167>. Date accessed: 10 feb. 2025. doi: https://doi.org/10.18103/mra.v13i1.6167.
Section
Research Articles

References

1. Sidonio RFJr, Malec L. Hemophilia B (factor IX deficiency). Hematol Oncol Clin North Am. 202;35 (6):1143-1155. doi: 10.1016/j.hoc.2021.07.008

2. WFH World Federation of Hemophilia Report on the Annual Global Survey 2023. Montreal: WFH 2024 https://wfh.org/research-and-data-collection/annual-global-survey/

3. Philipp C. The aging patient with hemophilia: complications, comorbidities, and management issues. Hematology 2010; 2010(1):191–196. doi: 10.1182/asheducation-2010.1.191.

4. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, III edition Haemophilia. 2020:26(Suppl 6): 1-158. doi: 10.1111/hae.14046.

5. Rezende SM, Neumann I, Angchaisuksiri P, et al. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the grading of recommendations assessment, development, and evaluation methodology. J. Thromb. Haemost, 2024;22(9);2629–2652. doi: 10.1016/j.jtha.2024.05.026.

6. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357(6):535-544. doi: 10.1056/NEJMoa067659.

7. Acharya SS. Advances in hemophilia and the role of current and emerging prophylaxis. Am J Manag Care 2016;22(5-Suppl):s116-125. Available at: https://pubmed.ncbi.nlm.nih.gov/27266808/

8. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Especializada e Temática. Coordenação-Geral de Sangue e Hemoderivados. Manual de hemofilia (Guide on the management of hemophilia). Brasília; Ministério da Saúde; II ed; 2015. 79 p.

9. Torres-Ortuño A. Adherence to prophylactic treatment. Blood Coagul Fibrinolysis. 2019;30(1S Suppl 1):S19-S21. doi: 10.1097/MBC.0000000000000822.

10. Iorio A, Fischer K, Blanchette V,et al. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost. 2017; 117(6):1023-1030. doi: 10.1160/TH16-12-0942.

11. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação nacional de medicamentos essenciais [National relation of essential medicines] Rename 2022. Brasília: Ministério da Saúde,2022.181p. Available at: http://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2022.pdf

12. Samelson-Jones BJ, George LA. Adeno-associated virus gene therapy for hemophilia. Annu Rev Med. 2023;74:231-247. doi: 10.1146/annurev-med-043021-033013

13. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-347. doi: 10.1038/nm1358. Erratum in: Nat Med. 2006; 12(5):592. Rasko, John [corrected to Rasko, John JE]; Rustagi, Pradip K [added].

14. Dhillon S. Fidanacogene elaparvovec: first approval. Drugs. 2024; 84(4):479-486. doi: 10.1007/s40265-024-02017-4. Epub 2024 Mar 12. PMID: 38472707.

15. Heo YA. Etranacogene dezaparvovec: first approval. Drugs. 2023;83(4):347-352. doi: 10.1007 /s40265-023-01845-0.

16. Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 2018; 131(9):1022-1031. doi: 10.1182/blood-2017-09-804419.

17. von Drygalski A, Gomez E, Giermasz A, et al. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy. Blood Adv. 2023;7(19 ):5671–5679. doi: 10.1182/bloodadvances.202200888649

18. Majowicz A, Nijmeijer B, Lampen MH, et al. Therapeutic hFIX activity achieved after single AAV5-hfix treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs. Mol Ther Methods Clin Dev. 2019;14:27–36. https://doi.org/10.1016/j.omtm.2019.05.009.

19. VandenDriessche T, Chuah MK. Hyperactive factor IX Padua: a game-changer for hemophilia gene therapy. Mol Ther. 2018;26(1):14-16. doi: 10.1016/j.ymthe.2017.12.007

20. Simioni P, Tormene D, Tognin G, et al. X-Linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361(17):1671–1675. doi: 10.1056/NEJMoa0904377.

21. Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B N Engl J Med. 2023;388(8):706–718. doi: 10.1056/NEJMoa2211644.

22. CSL Behring. LLC. HEMGENIX ® (etranacogene dezaparvovec-drlb) suspension, for intravenous infusion 2023. chrome-extension: //efaidnbmnnnibpcajpcglclefindmkaj/https://labeling.cslbehring.com/PI/US/Hemgenix/EN/Hemgenix-Prescribing-Information.pdf

23. Blair HA. Onasemnogene Abeparvovec: a review in spinal muscular atrophy. CNS Drugs. 2022; 36 (9):995-1005. doi: 10.1007/s40263-022-00941-1.

24. von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019;3(21): 3241-3247. doi: 10.1182/bloodadvances.2019000 811. Erratum in: Blood Adv. 2020;4(15):3668. doi: 10.1182/bloodadvances.2020002987.

25. Bolous NS, Chen Y, Wang H, et al. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood. 2021;138(18) :1677–1690. doi 10.1182/blood.2021010864.

26. Meier N, Fuchs H, Galactionova K, Hermans C, Pletscher M, Schwenkglenks M. Cost-effectiveness analysis of etranacogene dezaparvovec versus extended half-life prophylaxis for moderate-to-severe haemophilia B in Germany key points for decision makers. Pharmacoecon Open. 2024;8(3): 373–387. doi:10.1007/s41669-024-00480-z.

27. Capucho HC, Salomon FCR, Vidal AT, Louly PG, Santos VCC, Petramale CA. Incorporation of techonologies in health in Brazil: a new model for the Brazilian public health system (Sistema Único de Saúde - SUS). BIS, Bol Inst Saúde. 2020; 13 (3):215-222

28. Ferreira AA, Brum IV, Souza JL, Leite ICG. Cost analysis of hemophilia treatment in a Brazilian public blood center (Custo-análise do tratamento da hemofilia em um hemocentro público brasileiro). Cad. Saúde Colet. 2020;28(4):556-566 2020. doi: 10.1590/1414-462X202028040484.

29. BPS Sistema de compras federais. BPS - Banco de Preços em Saúde 2023. Available at: https://www.gov.br/saude/pt-br/acesso-a-informacao/banco-de-precos

30. Datasus. SIGTAP - sistema de gerenciamento da tabela de procedimentos, medicamentos e OPM do SUS 2023. Available at: http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jsp

31. Earley J, Piletska E, Ronzitti G, Piletsky S. Evading and overcoming AAV neutralization in gene therapy. Trends Biotechnol. 2023;41:836–845. doi: 10.1016/j.tibtech.2022.11.006

32. Ronzitti G, Gross DA, Mingozzi F. Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol. 2020;11:670. doi: 10.3389 /fimmu.2020.00670.

33. IBGE. Tabela 2645: Estimativas populacionais das medianas de altura e peso de crianças, adolescentes e adultos, por sexo, situação do domicílio e idade - Brasil e Grandes Regiões 2008. Rio de Janeiro:IBGE.

34. ISPOR. International Society for Pharmacoeconomics and Outcomes Research. Health care cost, quality and outcomes. 2009. Lawrenceville: ISPOR. 278p.

35. Pan American Health Organization. Health Technology Assessment. Available at https://www.paho.org/en/topics/health-technology-assessment , 22/12/2024

36. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13(4):419-22. doi: 10.1038/nm1549.

37. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371 (21):1994-2004. doi: 10.1056/NEJMoa1407309.

38. Chowdary P, Shapiro S, Makris M, et al. Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B. N Engl J Med. 2022 Jul 21;387(3):23 7-247. doi: 10.1056/NEJMoa2119913. PMID: 35857660.

39. Konkle BA, Walsh CE, Escobar MA, et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021;137(6):763-774. doi: 10.1182/blood. 2019004625.

40. de Jong YP, Herzog RW. AAV and hepatitis: cause or coincidence? Mol Ther. 2022; 30(9):2875-2876. doi: 10.1016/j.ymthe.2022.08.001

41. Anguela XM, High KA. Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec. Blood adv. 2024;8(7):1796-1803. doi: 10.1182/bloodadvances.2023010511.

42. Alshehri A, Dougherty JA, Beckman L, Svensson M. A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B. J Manag Care Spec Pharm. 2024 Oct;30(10):1178-1188. doi: 10.18553/ jmcp.2024.30.10.1178.

43. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia. 2003; Suppl 1:101-8; discussion 109-10. doi: 10.1046/j.1365-2516.9.s1.4.x.

44. Yan S, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Wilson M. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States. J Med Econ. 2024; 27(1):758-765. doi: 10.1080/13696998.2024.2351762.

45. George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377 (23):2215-2227. doi: 10.1056/NEJMoa1708538.

46. Cuker A, Kavakli K, Frenzel L, et al. Gene therapy with fidanacogene elaparvovec in adults with hemophilia B. N Engl J Med. 2024; 391 (12):1108-1118. doi: 10.1056/NEJMoa2302982.

47. Keam SJ. Concizumab: first approval. Drugs. 2023;83(11):1053-1059. doi: 10.1007/s40265-023-01912-6. Erratum in: Drugs. 2023;83(13):1253-1254. doi: 10.1007/s40265-023-01924-2.

48. Mullard A. FDA approves first anti-TFPI antibody for haemophilia A and B. Nat Rev Drug Discov. 2024; 23(12):884. doi: 10.1038/d41573-024-00175-4.

49. Mahlangu JN. Progress in the development of anti-tissue factor pathway inhibitors for haemophilia management. Front Med (Lausanne). 2021;8:670526. doi: 10.3389/fmed.2021.670526.

50. Harmatz P, Prada CE, Burton BK, et al. First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia B. Mol Ther. 2022;30(12):3587-3600. doi: 10.1016/j.ymthe.2022.10.010.

51. Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. Curr Med Res Opin. 2023;39(2):227-237. doi: 10.1080/03007995.2022.2133492

52. Arvanitakis A, Jepsen C, Andersson NG, Baghaei F, Astermark J. Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients. Haemophilia. 2024;30(3):671-677. doi: 10.1111/hae.15013.

53. George LA, Ragni MV, Rasko JEJ, et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol Ther. 2020;28(9):2073-2082. doi: 10.1016/j.ymthe.2020.06.001.

54. Cohen JP. Despite eye-popping $3.5 million price tag for gene therapy hemgenix, budget impact for most payers will be relatively small. Forbes, Dec 2, 2022

55. Kansteiner F, Becker Z, Liu A, Sagonowsky E, Dunleavy K. Most expensive drugs in the US in 2023. Fierce Pharma, May 22, 2023

56. Hermans C, Marino R, Lambert C, et al. Real-world utilisation and bleed rates in patients with haemophilia B who switched to recombinant factor IX fusion protein (rIX-FP): a retrospective international analysis. Adv Ther. 2020;37(6):2988-2998. doi: 10.1007/s12325-020-01300-6.

57. Chen P, Han S. (2022). An Update on the Current Management of Hepatitis B Virus in Special Populations. Med Res Arch. 2022;10(11). doi:10. 18103/mra.v10i11.3315

58. Brasil. Constituição da República Federativa do Brasil de 1988. Brasília, DF: Senado Federal; 1988. Available at: https://www.planalto.gov.br/ccivil_03/constituicao/constituicao.htm